Background: Radical resection of pelvic and low rectal malignancies leads to complex reconstructive challenges. Many pelvic reconstruction options have been described including primary closure, omental flaps, and various fasciocutaneous and myocutaneous flaps. Little consensus exists in the literature on which of the various options in the reconstructive armamentarium provides a superior outcome. The authors of this study set out to determine the costs and quality-of-life outcomes of primary closure, vertical rectus abdominus muscle flap, gluteal thigh flap, and gracilis flap to aid surgeons in identifying an optimal reconstructive algorithm.
Methods: A decision tree analysis was performed to analyze the cost, complications, and quality-of-life associated with reconstruction by primary closure, gluteal thigh flap, vertical rectus abdominus muscle flap, and gracilis flap. Costs were derived from Medicare reimbursement rates (FY2021), while quality-adjusted life-years were obtained from the literature.
Results: Gluteal thigh flap was the most cost-effective treatment strategy with an overall cost of $62,078.28 with 6.54 quality-adjusted life-years and an incremental cost-effectiveness ratio of $5,649.43. Gluteal thigh flap was always favored as the most cost-effective treatment strategy in our 1-way sensitivity analysis. Gracilis flap became more cost-effective than gluteal thigh flap, in the scenario where gluteal thigh flap complication rates increased by roughly 4% higher than gracilis flap complication rates.
Conclusion: Our data suggest that, when available, gluteal thigh flap be the first-line option for reconstruction of pelvic defects as it provides the best quality-of-life at the most cost-effective price point. However, future studies directly comparing outcomes of gluteal thigh flap to vertical rectus abdominus muscle and gracilis flap are needed to further delineate superiority.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.surg.2022.09.015 | DOI Listing |
Clin Pharmacol Ther
December 2024
Vir Biotechnology, Inc., San Francisco, California, USA.
Sotrovimab is a recombinant human monoclonal antibody for the early treatment of mild-to-moderate COVID- 19. A phase I, open-label, randomized, parallel-group study was conducted to investigate the pharmacokinetics, relative bioavailability, safety, and tolerability of two concentrations of sotrovimab administered intramuscularly at different injection sites in healthy volunteers. The study consisted of three parts (A, B, and C) and the pharmacokinetic results from Part A are reported herein.
View Article and Find Full Text PDFCureus
October 2024
Department of Obstetrics and Gynecology, General Hospital of Lamia, Lamia, GRC.
Herpes zoster (HZ), caused by the reactivation of the varicella-zoster virus (VZV), typically presents as a unilateral vesicular rash in a dermatomal pattern. Its occurrence in the genital area is rare and often misdiagnosed. We report the case of a 51-year-old woman who presented with sudden vulvar pain and burning, without a history of immunodeficiency or sexually transmitted infections.
View Article and Find Full Text PDFFront Oncol
October 2024
Orthopaedic Oncology, Department of Orthopaedics and Trauma Surgery, Ludwig-Maximilian-University (LMU) University Hospital, Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.
Introduction: Surgical site infections (SSI) are one of the most common complications after extensive sarcoma resections and represent a daily challenge. SSI occur in up to 50% of cases particularly in the peripelvic area. One possible approach to reduce infection rate is perioperative antibiotic prophylaxis.
View Article and Find Full Text PDFAntimicrob Agents Chemother
December 2024
GSK, Durham, North Carolina, USA.
Microsurgery
November 2024
Department of Plastic Reconstructive and Aesthetic Surgery, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!